

Patrick Durez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5820414/publications.pdf>

Version: 2024-02-01

113
papers

8,181
citations

94433

37
h-index

48315

88
g-index

117
all docs

117
docs citations

117
times ranked

7320
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114
2	Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis. <i>Science Translational Medicine</i> , 2010, 2, 52ra72.	12.4	774
3	Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. <i>Lancet, The</i> , 2008, 372, 375-382.	13.7	744
4	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIB, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2263-2271.	6.7	456
5	Golimumab, a human anti-tumor necrosis factor- β monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2272-2283.	6.7	387
6	Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. <i>Arthritis and Rheumatism</i> , 1997, 40, 249-260.	6.7	377
7	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 918-929.	13.7	311
8	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-blind, Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1788-1800.	5.6	284
9	Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008, 58, 964-975.	6.7	266
10	Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 863-869.	0.9	263
11	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014, 383, 321-332.	13.7	232
12	The anti-CD20 antibody rituximab reduces the Th17 cell response. <i>Arthritis and Rheumatism</i> , 2011, 63, 1507-1516.	6.7	154
13	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	13.7	145
14	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.9	130
15	Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 153.	1.9	128
16	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1607-1615.	0.9	125
17	Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. <i>Arthritis and Rheumatism</i> , 2007, 56, 3919-3927.	6.7	122
18	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1454-1462.	0.9	115

#	ARTICLE	IF	CITATIONS
19	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	30.7	105
20	Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R57.	3.5	104
21	One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. <i>Journal of Rheumatology</i> , 2014, 41, 414-421.	2.0	88
22	DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. <i>Arthritis Research and Therapy</i> , 2005, 7, R1063.	3.5	79
23	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.9	71
24	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 335-343.	0.9	71
25	Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium. <i>Arthritis and Rheumatology</i> , 2014, 66, 15-23.	5.6	70
26	Remission and immune reconstitution after T-cell-depleted stem-cell transplantation for rheumatoid arthritis. <i>Lancet, The</i> , 1998, 352, 881.	13.7	54
27	Listeria infections associated with infliximab: case reports. <i>Clinical Rheumatology</i> , 2007, 26, 2173-2175.	2.2	53
28	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. <i>RMD Open</i> , 2022, 8, e002012.	3.8	50
29	Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 208.	3.5	48
30	Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1287-1294.	0.9	47
31	Validation of the ABILHAND questionnaire as a measure of manual ability in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1098-1105.	0.9	43
32	Hepatitis C infection and membranoproliferative glomerulonephritis. <i>Lancet, The</i> , 1993, 341, 317.	13.7	42
33	Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. <i>Arthritis Research and Therapy</i> , 2006, 8, R112.	3.5	41
34	Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e113465.	2.5	41
35	Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF- α and upregulation of IL-10 release. <i>International Journal of Immunopharmacology</i> , 1999, 21, 581-587.	1.1	40
36	Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 628-632.	0.9	40

#	ARTICLE	IF	CITATIONS
37	Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 49-55.	1.9	40
38	Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 564-568.	0.9	39
39	Higher expression of TNF-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy. <i>Arthritis Research and Therapy</i> , 2016, 18, 19.	3.5	39
40	Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1-Year and 2-Year Clinical, Radiologic, and Physical Function Findings of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2013, 65, 1732-1742.	3.4	33
41	Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. <i>Journal of Rheumatology</i> , 2014, 41, 629-639.	2.0	33
42	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. <i>Arthritis and Rheumatology</i> , 2020, 72, 714-725.	5.6	33
43	Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2016, 68, 744-752.	3.4	32
44	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , 2018, 4, e000799.	3.8	31
45	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. <i>Arthritis Research and Therapy</i> , 2018, 20, 265.	3.5	29
46	Heterogeneity of Synovial Molecular Patterns in Patients with Arthritis. <i>PLoS ONE</i> , 2015, 10, e0122104.	2.5	29
47	Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 501-502.	1.2	28
48	Longterm Followup of Rituximab Therapy in Patients with Rheumatoid Arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2014, 41, 1761-1765.	2.0	28
49	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. <i>Journal of Rheumatology</i> , 2018, 45, 1085-1092.	2.0	28
50	Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. <i>Arthritis Research and Therapy</i> , 2010, 12, R77.	3.5	27
51	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. <i>Clinical Rheumatology</i> , 2018, 37, 2381-2390.	2.2	26
52	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1477-1486.	0.9	23
53	Spontaneous and cycloheximide-induced interleukin-10 mRNA expression in human mononuclear cells. <i>Molecular Immunology</i> , 1995, 32, 233-239.	2.2	20
54	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	1.9	20

#	ARTICLE	IF	CITATIONS
55	The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. <i>Arthritis Research and Therapy</i> , 2010, 12, R169.	3.5	18
56	Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 741-744.	0.9	18
57	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review. <i>Arthritis Research and Therapy</i> , 2021, 23, 3.	3.5	18
58	Epidemiological Review of Injuries in Rugby Union. <i>Sports</i> , 2015, 3, 21-29.	1.7	17
59	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020, 6, e001211.	3.8	17
60	Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. <i>Rheumatology</i> , 2021, 60, 5583-5594.	1.9	17
61	A Nationwide Survey on Patient's versus Physician's Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study. <i>PLoS ONE</i> , 2016, 11, e0166607.	2.5	16
62	A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 847-53.	2.0	16
63	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 85-100.	3.0	14
64	Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes. <i>Arthritis Care and Research</i> , 2014, 66, 1799-1807.	3.4	13
65	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	3.5	13
66	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011, 27, 315-325.	1.9	12
67	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021, 7, e001724.	3.8	12
68	Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 658-667.	0.8	12
69	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1640-1646.	0.9	12
70	Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment. <i>Engineering Applications of Artificial Intelligence</i> , 2006, 19, 819-828.	8.1	11
71	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 54-58.	2.2	11
72	Fasciae of the musculoskeletal system: normal anatomy and MR patterns of involvement in autoimmune diseases. <i>Insights Into Imaging</i> , 2018, 9, 761-771.	3.4	11

#	ARTICLE	IF	CITATIONS
73	Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. <i>RMD Open</i> , 2021, 7, e001646.	3.8	11
74	Responsiveness of the ABILHAND questionnaire in measuring changes in rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2011, 63, 135-141.	3.4	10
75	Paired Rheumatoid Arthritis Synovial Biopsies From Small and Large Joints Show Similar Global Transcriptomic Patterns With Enrichment of Private Specificity TCRB and TCR Signaling Pathways. <i>Frontiers in Immunology</i> , 2020, 11, 593083.	4.8	10
76	BONE MARROW ASPIRATION AS A DIAGNOSTIC TOOL FOR ACUTE TOXOPLASMOSIS IN A KIDNEY TRANSPLANT RECIPIENT. <i>Transplantation</i> , 1990, 50, 1054.	1.0	9
77	Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis. <i>Journal of Translational Medicine</i> , 2020, 18, 8.	4.4	9
78	Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. <i>Rheumatology International</i> , 2015, 35, 669-675.	3.0	8
79	Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 96.	3.5	8
80	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 539-548.	3.0	8
81	Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue. <i>Frontiers in Immunology</i> , 2021, 12, 724895.	4.8	8
82	Comparison between 3-point Dixon- and CHES-based OMERACT-recommended MRI protocols in hands of patients with suspicion of early rheumatoid arthritis. <i>European Journal of Radiology</i> , 2021, 134, 109412.	2.6	7
83	Ten-year Followup of Infliximab Therapy in Rheumatoid Arthritis Patients with Severe, Longstanding Refractory Disease: A Cohort Study. <i>Journal of Rheumatology</i> , 2014, 41, 1276-1281.	2.0	6
84	Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target. <i>Joint Bone Spine</i> , 2019, 86, 594-599.	1.6	6
85	Switching of biologics in RA patients who do not respond to the first biologic. <i>Joint Bone Spine</i> , 2018, 85, 395-397.	1.6	5
86	Contrast-enhanced T1-weighted Dixon water- and fat-only images to assess osteitis and erosions according to RAMRIS in hands of patients with early rheumatoid arthritis. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 439-445.	3.2	5
87	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. <i>Journal of Rheumatology</i> , 2022, 49, 133-141.	2.0	5
88	Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort. <i>Rheumatology</i> , 2021, 60, 5576-5582.	1.9	4
89	Is There a Future for Interleukin 17 Blocking Agents in Rheumatoid Arthritis?. <i>Journal of Rheumatology</i> , 2016, 43, 465-467.	2.0	3
90	Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. <i>Arthritis Care and Research</i> , 2020, 72, 959-964.	3.4	3

#	ARTICLE	IF	CITATIONS
91	Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos. <i>Acta Clinica Belgica</i> , 2022, 77, 233-240.	1.2	3
92	A Cross-Sectional and Longitudinal Study to Define Alarmins and A-SAA Variants as Companion Markers in Early Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 638814.	4.8	3
93	Severe panniculitis and polyarthritis caused by acinar cell carcinoma arising from an ectopic pancreas. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-222241.	0.5	3
94	A rare case of tuberculosis-induced hypercalcemia. <i>Biochemia Medica</i> , 2020, 30, 471-474.	2.7	3
95	MRI of Hands with Early Rheumatoid Arthritis: Usefulness of Three-Point Dixon Sequences to Quantitatively Assess Disease Activity. <i>Journal of the Belgian Society of Radiology</i> , 2022, 106, 1.	0.3	3
96	Anti-TNF Induced Sarcoidosis-Like Disease in Rheumatoid Arthritis Patients: Review Cases from the RA UCLouvain Brussels Cohort. <i>Rheumatology and Therapy</i> , 2022, 9, 763-770.	2.3	3
97	Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. <i>Rheumatology</i> , 2022, 61, 3246-3256.	1.9	3
98	Effects of raloxifene treatment on the phenotype of blood monocytes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 601-605.	1.4	2
99	Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1732-1736.	1.9	2
100	India ink artifact on Dixon out-of-phase images can be used as a landmark to measure joint space width at MRI. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 87-96.	3.2	2
101	Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. <i>RMD Open</i> , 2021, 7, .	3.8	2
102	An update on the adalimumab biosimilar landscape following approval of the first high-concentration biosimilar. <i>Immunotherapy</i> , 2022, 14, 235-252.	2.0	2
103	Predictive value of ACR core set parameters for the development of rheumatoid arthritis in patients with positive anti-cyclic citrullinated peptide antibodies and undifferentiated arthritis. <i>Rheumatology</i> , 2014, 53, 1347-1348.	1.9	1
104	Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study. <i>Acta Clinica Belgica</i> , 2017, 72, 424-428.	1.2	1
105	Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. <i>Clinical Rheumatology</i> , 2018, 37, 1417-1420.	2.2	1
106	Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitis. <i>BMJ Case Reports</i> , 2021, 14, e237713.	0.5	1
107	Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study. <i>BMC Rheumatology</i> , 2022, 6, 24.	1.6	1
108	P196 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2022, 61, .	1.9	1

#	ARTICLE	IF	CITATIONS
109	Caractéristiques initiales et résultats préliminaires du suivi de la cohorte CAP48 Polyarthrite Rhumatoïde d'adulte. Revue Du Rhumatisme (Edition Francaise), 2016, 83, A255-A256.	0.0	0
110	Rotation des biothérapies en cas de réponse inadéquate à un premier agent biologique dans la polyarthrite rhumatoïde. Revue Du Rhumatisme Monographies, 2018, 85, 15-18.	0.0	0
111	233 Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. Rheumatology, 2018, 57, .	1.9	0
112	Réponse clinique précoce et progression radiographique à long terme dans la polyarthrite rhumatoïde d'adulte: la rémission clinique à 6 mois reste l'objectif à atteindre. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 367-372.	0.0	0
113	OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Rheumatology, 2022, 61, .	1.9	0